• Lantern Pharma received a USPTO Notice of Allowance for a patent application covering biomarker-guided use of LP-184 (zirdafulven) in solid tumors.
• Claims cover selecting patients with certain solid tumor cancers based on elevated PTGR1, PTPN14, and ASPH expression in tumor samples.
• LP-184 is a PTGR1-activated prodrug designed to induce DNA damage in tumors with deficient DNA damage repair pathways.
• A 63-patient Phase 1a trial in advanced solid tumors reported a 45% disease control rate at or above the effective therapeutic dose.
• The company plans multiple precision oncology Phase 1b/2 trials for LP-184 in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723600415) on July 23, 2026, and is solely responsible for the information contained therein.